Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
MM&M2d
What will happen to Medicare drug pricing negotiations under Trump?
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
No, Trump did not get rid of Medicare’s $35 insulin cap
Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.
Hosted on MSN4d
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
Sierra Sun Times4d
Democrat U.S. Senators Urge President Trump to Reject Big Pharma’s Push to End Medicare Price Negotiations, Protect Medicare Enrollees
Democrat U.S. Senators Urge President Trump to Reject Big Pharma’s Push to End Medicare Price Negotiations, Protect Medicare Enrollees ...
Modern Healthcare5d
Trump urged to keep Biden’s Medicare drug price cuts
A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end ...
Trump Urged by Democratic Senators to Keep Lowered Drug Prices
A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden ...
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...